` MASI (Masimo Corp) vs S&P 500 Comparison - Alpha Spread

MASI
vs
S&P 500

Over the past 12 months, MASI has outperformed S&P 500, delivering a return of 26% compared to the S&P 500's 9% growth.

Stocks Performance
MASI vs S&P 500

Loading
MASI
S&P 500
Add Stock

Performance Gap
MASI vs S&P 500

Loading
MASI
S&P 500
Difference
www.alphaspread.com

Performance By Year
MASI vs S&P 500

Loading
MASI
S&P 500
Add Stock

Competitors Performance
Masimo Corp vs Peers

Masimo Corp
Glance View

Economic Moat
None
Market Cap
8.9B USD
Industry
Health Care

Masimo Corp., a pioneering force in noninvasive monitoring technologies, was founded in 1989 by Joe Kiani, who envisioned a healthcare landscape imbued with precision and accessibility. The company rose to prominence with its innovative pulse oximetry technology, a tool crucial for measuring oxygen levels in patients' blood. Unlike traditional methods, Masimo's technology utilizes proprietary signal extraction techniques that allow it to deliver accurate readings even in challenging conditions such as movement or low perfusion. This innovation not only revolutionized patient monitoring but also secured Masimo significant market share within hospitals and healthcare facilities worldwide. Their devices, known for their reliability, feed into a recurring revenue model, as hospitals and medical professionals constantly require new sensors and related consumables to operate the equipment effectively. In addition to pulse oximetry, Masimo has skillfully expanded its portfolio to encompass advanced monitoring systems such as those measuring brain function and hydration levels, offering a comprehensive suite of solutions for enhanced patient care. They have ventured into consumer health as well, with devices that allow people to monitor their health metrics at home. This broadening of scope positions Masimo as a versatile player across both professional and consumer markets. By continually investing in research and development, Masimo aims to address unmet clinical needs and open new revenue streams, thus sustaining its growth trajectory in the competitive landscape of medical technology. Through strategic partnerships and acquisitions, the company has consistently augmented its capabilities, solidifying a robust financial performance anchored in its commitment to innovation and quality.

MASI Intrinsic Value
129.85 USD
Overvaluation 21%
Intrinsic Value
Price
Back to Top